Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 35 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

51%

18 trials in Phase 3/4

Results Transparency

32%

9 of 28 completed trials have results

Key Signals

2 recruiting9 with results

Enrollment Performance

Analytics

Phase 3
17(48.6%)
Phase 2
9(25.7%)
Phase 1
6(17.1%)
Early Phase 1
1(2.9%)
N/A
1(2.9%)
Phase 4
1(2.9%)
35Total
Phase 3(17)
Phase 2(9)
Phase 1(6)
Early Phase 1(1)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT06911216Early Phase 1Completed

A Pharmacokinetics (PK) Study in Healthy Adults

Role: lead

NCT06666855Phase 3Recruiting

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Role: lead

NCT06683651Phase 3Recruiting

A Study in Chinese Patients With Acquired Blepharoptosis

Role: lead

NCT05503901Phase 3Completed

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT02981446Phase 3Completed

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Role: lead

NCT05495061Phase 3Completed

A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT05905653Phase 1Completed

Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Role: lead

NCT06146881Phase 2Unknown

Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia

Role: collaborator

NCT03822559Phase 3Completed

A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT04214821Phase 1Unknown

The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Role: collaborator

NCT04212429Phase 1Unknown

The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Role: collaborator

NCT04212078Phase 1Unknown

Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime

Role: collaborator

NCT03329638Phase 2Completed

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

Role: lead

NCT03197480Phase 4Unknown

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

Role: collaborator

NCT03216096Phase 1Completed

Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

Role: lead

NCT02888210Phase 3Completed

A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Role: lead

NCT02623738Phase 2Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Role: lead

NCT02822742Phase 3Completed

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Role: lead

NCT02822729Phase 3Completed

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Role: lead

NCT02573610Phase 3Completed

Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery

Role: lead